Aarey Drugs & Pharmaceuticals Ltd FY26 Results: Profit Soars 231%

Q4 FY26 Profit: ₹1.56 crore
Q4 FY26 Revenue: ₹189.47 crore

Reader Takeaway: Strong profit and revenue growth is offset by an auditor's note on balance verification.

What just happened

Aarey Drugs & Pharmaceuticals Ltd has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a significant year-on-year increase in profitability.

Why this matters

The company's performance in Q4 FY26 shows robust growth, with profit for the period rising by 231.59% to ₹1.56 crore, compared to ₹0.47 crore in the same quarter of the previous year. Revenue from operations also saw a substantial jump of 75.27%, reaching ₹189.47 crore from ₹108.10 crore.

The backstory

During FY 2025-2026, Aarey Drugs & Pharmaceuticals had raised capital through convertible warrants. The company has reported that 25% of the consideration, amounting to ₹7.98 crore, has been received and utilized. This capital infusion is intended to support business funding and potential restructuring.

What changes now

With the final audited results for FY26 now available, investors have a clearer picture of the company's financial standing. The positive revenue and profit trends for the quarter are encouraging. However, the auditor's emphasis of matter requires attention.

Risks to watch

The statutory auditor, Motilal & Associates LLP, has highlighted in an 'Emphasis of Matter' note that closing balances for debtors and creditors are relied upon as per the company's books because third-party confirmations were unavailable. These balances are thus subject to management representation, indicating a potential area for scrutiny regarding the accuracy of financial figures.

Peer comparison

(No peer comparison data available in the filing).

Context metrics (time-bound)

• Revenue from Operations:
  • Q4 FY 2026: ₹189.47 crore
  • FY 2026: ₹472.27 crore
• Profit for the Period:
  • Q4 FY 2026: ₹1.56 crore
  • FY 2026: ₹3.97 crore
• Total Assets (as of March 31, 2026): ₹297.25 crore
• Funds Utilized from Warrants (FY 2026): ₹7.98 crore

What to track next

Investors should closely monitor the company's operational efficiency and how effectively the remaining funds raised from the convertible warrants are deployed. The verification of debtor and creditor balances, as flagged by the auditor, will also be a key point to track in future financial reports.